Evidence map›Paper›PMID 38183631›Full record

ArticleAdvances in wound care2024

Use of Therapeutic RNAs to Accelerate Wound Healing in Diabetic Rabbit Wounds.

Brandon J Sumpio, Anne Dallas, Adam G Berger, Zhuqing Li, Enya Wang, Ikram Mezghani, Mauricio Contreras, Georgios Theocharidis, Heini Ilves, Paula T Hammond and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in wound care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Brandon J SumpioRongxiang Xu Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Anne DallasSomaGenics, Inc., Santa Cruz, California, USA.
Adam G BergerHarvard-MIT Division of Health Sciences and Technology, Department of Chemical Engineering, Institute for Soldier Nanotechnologies, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Zhuqing LiRongxiang Xu Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Enya WangRongxiang Xu Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Ikram MezghaniRongxiang Xu Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Mauricio ContrerasRongxiang Xu Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Georgios TheocharidisRongxiang Xu Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-8895-9130
Heini IlvesSomaGenics, Inc., Santa Cruz, California, USA.
Paula T HammondHarvard-MIT Division of Health Sciences and Technology, Department of Chemical Engineering, Institute for Soldier Nanotechnologies, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Brian H JohnstonSomaGenics, Inc., Santa Cruz, California, USA.
Aristidis VevesRongxiang Xu Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-8372-3607
Beth Israel Deaconess Medical Center · USSomaGenics (United States) · USInstitute for Soldier Nanotechnologies · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Kristin A Knouse · 1985 to 2026
$93.9M
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticlesR01CA235375 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond, Darrell J Irvine · 2019 to 2026
$2.3M
A novel sshRNA-antimiR combination therapy for accelerating healing of diabetic foot ulcersR43DK121668 · NIDDK · SOMAGENICS, INC. · PI JOHNSTON, BRIAN H. · 2019 to 2019
$300k
Controlled release of RNA-targeting therapy to promote healing of diabetic ulcersF30DK130564 · NIDDK · HARVARD MEDICAL SCHOOL · PI BERGER, ADAM G · 2021 to 2025
$257k
NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA235375NIDDK NIH HHS F30 DK130564NIDDK NIH HHS R43 DK121668NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, ExperimentalDiabetic FootMicroRNAsWound HealingAnimalsBandagesDisease Models, AnimalRabbitsMicroRNAsantimirdiabetic woundsmicroRNAmiR-210PHD2sshRNAwound healing

Identifiers

PMID38183631
PMCPMC11535488
OpenAlexW4390640195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.